# Clinical Research on Cannabis Derivatives for Autism > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-derivatives-autism-clinical-trials/ > **Published:** 2026-04-25T13:52:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:54:49-04:00 > **Clinical Summary:** Explore cannabis derivatives autism clinical trials showing potential for behavioral and anxiety symptom relief in autism spectrum disorder. --- #### Clinical Takeaway Cannabis derivatives, particularly CBD-dominant formulations, show potential for reducing behavioral challenges and anxiety in autism spectrum disorder based on available [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). Evidence remains limited by small sample sizes and heterogeneous outcome measures, requiring larger randomized controlled trials before clinical recommendations can be established. Current research suggests cannabis derivatives may address specific symptoms like irritability and self-injurious behaviors rather than core autism features. ### #16 Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review. **Citation:** Riera Rachel et al. *Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.* Journal of clinical pharmacology. 2025. PMID: 40605143. **Study type:** Journal Article, Systematic Review  |  **Topic area:** Autism  |  **CED Score:** 11 Design: 5 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: 0 **Abstract:** Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism-diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40605143/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12555098/)[DOI ↗](https://doi.org/10.1002/jcph.70068) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Derivatives & Autism Spectrum Disorder: Evidence from Clinical Research](https://cedclinic.com/cannabis-derivatives-autism-spectrum-disorder-evidence/) A detailed review of [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on cannabis derivatives for autism spectrum disorder, highlighting current findings and limitations. [Read More](https://cedclinic.com/cannabis-derivatives-autism-spectrum-disorder-evidence/) [Cannabinoids for Autism: Clinical Evidence Reviewed](https://cedclinic.com/therapeutic-cannabis-autism-systematic-review/) An evidence-based review of cannabinoids in autism, focusing on clinical trial outcomes and therapeutic potential. [Explore Insights](https://cedclinic.com/therapeutic-cannabis-autism-systematic-review/) [Endocannabinoid System Research: Cannabis for Autism](https://cedclinic.com/cannabis-derivatives-autism-spectrum-disorder-research/) Research exploring the role of the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in autism and the therapeutic implications of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). [Learn More](https://cedclinic.com/cannabis-derivatives-autism-spectrum-disorder-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Clinical%20Research%20on%20Cannabis%20Derivatives%20for%20Autism&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-derivatives-autism-clinical-trials%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-derivatives-autism-clinical-trials%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Clinical%20Research%20on%20Cannabis%20Derivatives%20for%20Autism%20https%3A%2F%2Fcedclinic.com%2Fcannabis-derivatives-autism-clinical-trials%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).